Semaglutide-Glycine-Cyanocobalamin Injectable recalled over sterility concerns

Recall date

March 6, 2026

Source

U.S. Food & Drug Administration (FDA) — enforcement report

Official notice title

PAYLESS COMPOUNDERS, LLC recalls Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Bea…

Recall number

D-0471-2026

FDA classification

Class II

Brand / firm

PAYLESS COMPOUNDERS, LLC

Sold / distributed

OR

Why it was recalled

Lack of Assurance of Sterility

Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What was recalled

Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR